Upconversion of light for use in optogenetic methods

US9522288B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9522288-B2
Application numberUS-201113882703-A
CountryUS
Kind codeB2
Filing dateNov 4, 2011
Priority dateNov 5, 2010
Publication dateDec 20, 2016
Grant dateDec 20, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are compositions comprising lanthanide-doped nanoparticles which upconvert electromagnetic radiation from infrared or near infrared wavelengths into the visible light spectrum. Also provided herein are methods activating light-responsive opsin proteins expressed on plasma membranes of neurons and selectively altering the membrane polarization state of the neurons using the light delivered by the lanthanide-doped nanoparticles.

First claim

Opening claim text (preview).

What is claimed is: 1. A method to depolarize the plasma membrane of a neural cell in an individual comprising: (a) placing a plurality of lanthanide-doped nanoparticles in proximity to the neural cell; and (b) exposing the plurality of nanoparticles to electromagnetic radiation in the infrared (IR) or near infrared (NIR) spectrum, wherein the nanoparticles comprise NaYF 4 :Ytterbium/X/Gadolinium, wherein X is Erbium (Er), Thulium (Tm), or Er/Tm, wherein the electromagnetic radiation in the IR or NIR spectrum is upconverted into light in the visible spectrum by the nanoparticles, and wherein a light-responsive opsin is expressed on the plasma membrane of the neural cells and activation of the opsin by the light in the visible spectrum induces the depolarization of the plasma membrane. 2. A method to depolarize the plasma membrane of a neural cell in an individual comprising: (a) administering a polynucleotide encoding a light-responsive opsin to an individual, wherein the light-responsive protein is expressed on the plasma membrane of a neural cell in the individual and the opsin is capable of inducing membrane depolarization of the neural cell when illuminated with light; (b) administering a plurality of lanthanide-doped nanoparticles in proximity to the neural cell, wherein the nanoparticles comprise NaYF 4 :Ytterbium/X/Gadolinium, wherein X is Erbium (Er), Thulium (Tm), or Er/Tm; and (c) exposing the plurality of nanoparticles to electromagnetic radiation in the infrared (IR) or near infrared (NIR) spectrum, wherein the electromagnetic radiation in the IR or NIR spectrum is upconverted into light in the visible spectrum and the activation of the opsin by the light in the visible spectrum induces the depolarization of the plasma membrane. 3. The method of claim 1 , wherein the light-responsive opsin comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:5 or 8. 4. The method of claim 1 , wherein the light-responsive opsin comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:6, 7, 9, 10, or 11. 5. The method of claim 1 , wherein X is Tm. 6. The method of claim 1 , X is Er. 7. The method of claim 1 , wherein the electromagnetic radiation in the IR or NIR spectrum is upconverted into light having a wavelength of about 450 nm to about 550 nm. 8. The method of claim 1 , wherein the electromagnetic energy in the IR or NIR spectrum is upconverted into light having a wavelength corresponding to red, yellow, or amber light. 9. The method of claim 1 , wherein the electromagnetic energy in the IR or NIR spectrum is upconverted into light having a wavelength corresponding to green or blue light. 10. The method of claim 1 , wherein the individual is a non-human animal. 11. The method of claim 1 , wherein the individual is a human. 12. The method of claim 1 , wherein the neural cell is a neural cell in the central nervous system. 13. The method of claim 1 , wherein the neural cell is a neural cell in the peripheral nervous system. 14. A method to hyperpolarize the plasma membrane of a neural cell in an individual comprising: (a) placing a plurality of lanthanide-doped nanoparticles in proximity to the neural cell; and (b) exposing the plurality of nanoparticles to electromagnetic radiation in the infrared (IR) or near infrared (NIR) spectrum, wherein the nanoparticles comprise NaYF 4 :Ytterbium/X/Gadolinium, wherein X is Erbium (Er), Thulium (Tm), or Er/Tm, wherein the electromagnetic radiation in the IR or NIR spectrum is upconverted into light in the visible spectrum by the nanoparticles, and wherein a light-responsive opsin is expressed on the plasma membrane and activation of the opsin by the light in the visible spectrum induces the hyperpolarization of the plasma membrane. 15. A method to hyperpolarize the plasma membrane of a neural cell in an individual comprising: (a) administering a polynucleotide encoding a light-responsive opsin to an individual, wherein the light-responsive protein is expressed on the plasma membrane of a neural cell in the individual and the opsin is capable of inducing membrane hyperpolarization of the neural cell when illuminated with light; (b) administering a plurality of lanthanide-doped nanoparticles in proximity to the neural cell, wherein the nanoparticles comprise NaYF 4 :Ytterbium/X/Gadolinium, wherein X is Erbium (Er), Thulium (Tm), or Er/Tm; and (c) exposing the plurality of nanoparticles to electromagnetic radiation in the infrared (IR) or near infrared (NIR) spectrum, wherein the electromagnetic radiation in the IR or NIR spectrum is upconverted into light in the visible spectrum and the activation of the opsin by the light in the visible spectrum induces the hyperpolarization of the plasma membrane. 16. The method of claim 14 , wherein the light-responsive opsin comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1 or SEQ ID NO:4. 17. The method of claim 14 , wherein X is Tm. 18. The method of claim 14 , wherein X is Er. 19. The method of claim 14 , wherein the electromagnetic energy in the IR or NIR spectrum is upconverted into light having a wavelength of about 450 nm to about 550 nm. 20. The method of claim 14 , wherein the electromagnetic energy in the IR or NIR spectrum is upconverted into light having a wavelength corresponding to red, yellow, or amber light. 21. The method of claim 14 , wherein the electromagnetic energy in the IR or NIR spectrum is upconverted into light having a wavelength corresponding to green or blue light. 22. The method of claim 14 , wherein the individual is a non-human animal. 23. The method of claim 14 , wherein the individual is a human. 24. The method of claim 14 , wherein the neural cell is a neural cell in the central nervous system. 25. The method of claim 14 , wherein the neural cell is a neural cell in the peripheral nervous system. 26. A system comprising: a) lanthanide-doped nanoparticles comprising NaYF 4 :Ytterbium/X/Gadolinium, wherein X is Erbium (Er), Thulium (Tm), or Er/Tm; b) a nucleic acid comprising a nucleotide sequence encoding a light-responsive polypeptide; and c) a source of infrared or near infrared electromagnetic radiation. 27. The method of claim 2 , wherein the light-responsive protein comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:5, 6, 7, 8, 9, 10, or 11. 28. The method of claim 2 , wherein X is Tm. 29. The method of claim 2 , wherein X is Er. 30. The method of claim 15 , wherein the light-responsive opsin comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1 or SEQ ID NO:4. 31. The method of claim 15 , wherein X is Tm. 32. The method of claim 15 , wherein X is Er. 33. The system of claim 26 , wherein the light-responsive polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:5, 6, 7, 8, 9, 10, or 11. 34. The system of claim 26 , wherein the light-responsive polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1 or SEQ ID NO:4. 35. The system of claim 26 , wherein X is Tm. 36.

Assignees

Inventors

Classifications

  • Coloured light · CPC title

  • Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers · CPC title

  • Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} · CPC title

  • Optical stimulation for exciting neural tissue · CPC title

  • viral genome or elements thereof as genetic vector · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9522288B2 cover?
Provided herein are compositions comprising lanthanide-doped nanoparticles which upconvert electromagnetic radiation from infrared or near infrared wavelengths into the visible light spectrum. Also provided herein are methods activating light-responsive opsin proteins expressed on plasma membranes of neurons and selectively altering the membrane polarization state of the neurons using the light…
Who is the assignee on this patent?
Deisseroth Karl, Anikeeva Polina, Univ Leland Stanford Junior
What technology area does this patent fall under?
Primary CPC classification A61N5/062. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).